Wellington Management Group
SAGE

Wellington Management Group’s Sage Therapeutics SAGE Stock Holding History

Wellington Management Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-98
Closed -$770K – 2307
2017
Q4 		$770K Buy
+98
New +$9.5K ﹤0.01% 1955

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wellington Management Group's SAGE Position: Q3 2024 in Review

Wellington Management Group sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 39,645 shares — an estimated $431K sold.

Wellington Management Group first reported a position in SAGE in Q2 2017 and held it in 28 quarters. The position peaked at $401M in Q2 2019. 175 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • Wellington Management Group reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Wellington Management Group sold 39,645 Sage Therapeutics shares in Q3 2024, an estimated $431K.
  • Wellington Management Group first reported a position in Sage Therapeutics in Q2 2017 and held it in 28 quarters.
  • Wellington Management Group's Sage Therapeutics position peaked at $401M in Q2 2019.
  • 175 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Wellington Management Group's 13F filing for Q3 2024, filed 14 Nov 2024.